

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 35/74, A23K 1/16	A1	(11) International Publication Number: WO 93/13786
		(43) International Publication Date: 22 July 1993 (22.07.93)

(21) International Application Number: PCT/GB93/00065

(22) International Filing Date: 13 January 1993 (13.01.93)

(30) Priority data:
9200891.1 16 January 1992 (16.01.92) GB(71)(72) Applicant and Inventor: MANN, Stephen, Philip [GB/
GB]: 29 London Road, Harston, Cambridgeshire CB2
5QQ (GB).(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7
Eldon Street, London EC2M 7LH (GB).(81) Designated States: AU, BB, BG, BR, CA, FI, GB, HU, JP,
KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD,
UA, US, European patent (AT, BE, CH, DE, DK, ES,
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI pa-
tent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN,
TD, TG).**Published***With international search report.
Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.*

(54) Title: FORMULATION AND USE OF MICROORGANISMS IN TREATING LIVESTOCK

(57) Abstract

For therapeutic use, and particularly for promoting growth or weight gain in livestock under intensive husbandry, a formulation comprises a first microorganism capable of producing lactic acid in the gastrointestinal tract of the animal and a second microorganism capable of producing a bactericide to which the microorganisms are resistant. The formulation may also comprise the means for digesting fibre and/or lactoperoxidase.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CJ	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MD	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

FORMULATION AND USE OF MICROORGANISMS
IN TREATING LIVESTOCK

Field of the Invention

This invention relates to a formulation of
5 microorganisms suitable for administration to an animal,
for therapeutic purposes or to promote growth, weight gain
or another desirable aim in commercial livestock.

Background of the Invention

In the production and growth of all animals, it is
10 possible to identify periods of vulnerability to infection
of the gastrointestinal tract (GIT), e.g. parturition and
weaning, and other periods of a traumatic nature that are
generally referred to as "stress". During these periods of
change, the first manifestation of deleterious effects
15 occurring is usually a loosening of bowel function and
diarrhoea. In extreme cases, such symptoms can lead to the
onset of dehydration, and ultimately death. The effect of
sub-acute infections is a marked check in the animals'
growth, that can even lead to a loss in weight.

20 In the wild, although the periods of "stress" occur,
they prove less traumatic, as seen by the reduced
occurrence of the symptoms described above. By contrast,
under conditions of normal and intensive husbandry, the
effects of "stress" may be both intensified and prolonged,
25 and additional traumas such as maternal separation,
transport, human handling and unusual environments may be
introduced.

In current practice of intensive husbandry in pigs,
antibiotics such as tylosin are added to the animal feed to
30 prevent or reduce GIT infections. Growth of the animals is
thus promoted, when compared with untreated controls, by
preventing the onset of the debilitating effects of the GIT
infections. The addition of copper to the feed is also
common practice, but the mechanism of action is uncertain.
35 It has however been shown that the presence of copper,
under certain conditions, can lead to the production of

H₂O₂, which is also produced by the action of bacteria in the GIT.

Summary of the Invention

5 A novel formulation of microorganisms, according to the present invention, is both capable of producing lactic acid in the GIT and also of producing (directly or indirectly. in situ), a bactericide to which the microorganisms in the formulation are resistant.

Description of the Invention

10 The microorganisms in the novel formulation severally and collectively produce compounds and enzymes that encourage the establishment of a predominant and benign flora in the GIT of mammalian, avian and piscine species. The establishment of such a flora prevents the onset of
15 those gastrointestinal diseases caused by the establishment of an alternative and deleterious flora in the intestine.

The mode of action of these bacteria is to produce antimicrobial enzymes, bactericides and bacteriostats which prevent the establishment of bacteria other than those
20 administered. This by contrast to the disadvantages associated with current techniques for achieving the same aims, i.e. by using a combination of aseptic husbandry with the addition of antibiotics and high concentrations of copper to animal feeds.

25 The principles described herein are applicable to a wide variety of animal species and commercial practices. The establishment of appropriate benign flora may be considered in the GIT of many animals that are used for the commercial production of meat, milk and fish. In addition,
30 since an object of the invention is to improve the health and well-being of animals in general, its use and applicability can be extended to draught animals, companion animals and humans.

A first microorganism in the novel formulation has the
35 capability of producing lactic acid in the GIT. This microorganism is, for example, of the genus Lactobacillus or Enterococcus. Either or both genera may be used; they

ar distinguished by th ir ability to utilise sugars such as glucose or lactose or, in the case of Enterococcus, to utilise starch, to produce lactic acid and thus reduce th local pH. The choice of microorganism will depend on th
5 locus at which it is desired to give the desired effect; for example, microorganisms of the genus Lactobacillus produce lactic acid at a more acid pH than those of the genus Enterococcus. Species of each of these genera that may be used are L. kasei, L. aminosum, L. fermentum, E.
10 faecalis and E. faecium. A mixture of more than one of each such microorganism may be used.

A second microorganism that is used is capable of producing a bactericide, e.g. by providing a substrate for lactoperoxidase, to produce peroxide. The oth r
15 microorganisms in the formulation should be resistant to that bactericide. Such a bactericide is capable of combating microorganisms that are the positive agent of enteric disorders, e.g. Staphylococcus aureus, E. coli and Salmonella.

20 The use of microorganisms ensures that the desired effect is produced locally. The various microorganisms in the formulation should be compatible, e.g. capable of growing together. Fast growth at the locus of action is desirable. The microorganisms may be selected for various
25 characteristics, e.g. resistance to commercial antibiotics and also bile acids, that make them suitable for their intended use.

The formulation may be supplemented with enzymes, or microorganisms producing enzymes, which digest fibre. Such
30 enzymes include arabinase and xylanase. Another useful enzyme is glucose oxidase, to produce (additional) peroxide. In addition, enzymes or biocatalysts producing free radicals from peroxide, e.g. lactoperoxidase, may be added to supplement or replace the natural enzymes found in
35 milk. Such free radicals have a disinfectant eff ct on some organisms that are generally not effective on the sel. cted strains in vivo.

A formulation of the invention can be used initially with the administration of conventional antibiotics. However, its continuing administration allows the amount of tylosin, virginiamycin or similar antibiotic to be reduced, and the requirement for copper in animal feeds can also thus be reduced or prevented. The microorganisms that are used in the novel formulation are selected for their ability to produce compounds such as bacteriocins and other such compounds in sufficient quantities to prevent the establishment of the deleterious bacteria in the GIT (e.g. E. coli, Salmonella etc.). The bacteria can be isolated from wild or cross-bred animals kept under non-intensive husbandry conditions. The quantities of the antimicrobial produced by these bacteria, however, remains small compared with the concentrations of antibiotics currently added to animal feeds. The possibility of the emergence of resistant strains is therefore much reduced. Further, by using a number of such compounds, the possibility of undesirable bacteria establishing resistance to a single agent is reduced.

Anti-bacterial compounds in this context will cover a wide range of compounds and are not confined to those generally referred to as antibiotics, though the production of antibiotics in vivo is part of the synergic effects that may be observed. The anti-bacterial compounds include those that produce bacteriocins, lactic acid, peroxide and enzymes. In addition, enzymes may be added to the formulation prior to ingestion, to enhance the establishment of the bacteria. Thus the inclusion of amylase and/or peroxidase will assist in the establishment of the desired flora.

The establishment of the desirable and benign flora depends on the selection of complementary species and strains that will establish themselves in most if not all of the ecological niches that are to be found in the GIT. Such ecological areas could under other conditions harbour undesirable organisms. The selected microorganisms must,

however, be sufficiently compatible to be specific to a particular environment, or resistant to the metabolic products of the other organisms to be used.

The desired flora must be established in competition with an already established flora. In the GIT of young animals, it is necessary to saturate as far as is possible the environment of the young animal with the desired flora. To this end, the formulation is fed to animals prior to parturition, following an intense course of administration of the formulation after administration of a course of antibiotics, or together with a compatible antibiotic. The administration of the formulation to the young animals, post-parturition, is preferably immediate and supplemented with a continuous administration with the feed. For this purpose, and in consideration of the processes of preparation of commercial animal feeds, strains of the organisms are preferably selected or produced that are resistant to the temperatures, e.g. 45°C or more, encountered during the manufacturing and pelleting processes.

By way of illustration only, the invention will now be described in terms of a formulation suitable for use in pigs. The intention is to remove synthetic antibiotics and copper from feed. It derives from observations that the flora in the GIT of wild-type pigs, kept under non-intensive conditions of husbandry, varies with age, and that a number of species tend to dominate during the stages of development. Three genera are found consistently: Lactobacilli, Enterococci and Bacilli. Of these, the E. faecalis and E. faecium predominate during the early stages of the animals' life. Lactobacilli are present from the earliest stages of life through to adulthood. Bacilli are present throughout, but become particularly numerous with the onset of an adult diet.

This flora is notable for a number of reasons:

1. The bacteria all grow at low values of pH and all produce acid (usually but not exclusively lactic acid).

2. The Bacilli in particular produce anti-bacterial compounds (e.g. bacitracin and polymyxin) while the Enterococci appear to be resistant to the release of such compounds (particularly bacitracin).

5 3. All these bacteria can use lactose as a carbon source and therefore have the ability to predominate in the presence of a milk diet containing lactose.

4. In addition, the organisms as a whole can use a wide variety of carbon sources including structural (plant) polysaccharides which enables them to colonise the GIT over
10 all stages of the animals' life.

5. The Lactobacilli and the Streptococci all produce peroxide which in combination with the lactoperoxidase in milk and saliva produces a natural bactericide. This
15 should permit the removal of copper from the diet since one putative mechanism for the copper in the diet is the production of peroxide in the presence of ascorbic acid.

Example

20 A formulation for use in pigs (but also other animals, e.g. man) is composed of four strains selected to show heat tolerance. Each strain is used at 10^9 cfu/g.

	Growth at (°C)	Resistant to (°C)
<u>Lactobacillus</u>	50	?
<u>Enterococcus faecalis</u>	45-50	60-65
<u>Enterococcus faecium</u>	45-50	60-65
<u>Bacillus licheniformis</u>	55-60	spores 110°C

30

35 All strains are capable of anaerobic growth and of utilising lactose and, except for the E. faecium, sucrose. Two strains of Bacillus are used, each capable of utilising arabinose, starch, pectin and araban, of growth on beet pulp, of inhibiting S. aureus, Salmonella and E. coli, and of producing xylanase and arabinofuranase, and each resistant to the antibiotics bacitracin, virginiamycin and

tylosin (to a degree), and to porcine bile extract. They each grow in the relatively high pH of the hind gut.

The other strains (Lactobacillus and Enterococcus) are producers of lactate and all are resistant to porcine bile extract and the antibiotics given above, except that
5 Lactobacillus and E. faecalis strains may not be resistant to bacitracin. This apparent disadvantage is countered by the practical aspect that these strains grow at low pH and are not affected by bacitracin in the upper intestine,
10 where the production of lactate is important.

The formulation may be supplemented by the addition of one or more enzymes selected from peroxidase, lipase, glucose oxidase, amylase and glucanase.

In initial trials, this formulation has been shown to
15 allow the replacement of antibiotic feed additives and copper in pigs, while mimicking the beneficial effects of such additives. A reduction in the presence of harmful microorganisms, as evidenced by the absence of the MMA syndrome, was observed.

CLAIMS

1. A formulation of microorganisms suitable for administration to an animal, comprising a first microorganism capable of producing lactic acid in the gastrointestinal tract of the animal and a second microorganism capable of producing a bactericide to which the microorganisms are resistant.
2. A formulation according to claim 1, wherein the first microorganism is a Lactobacillus.
3. A formulation according to claim 1 or claim 2, wherein the first microorganism is an Enterococcus.
4. A formulation according to any preceding claim, wherein the second microorganism is a Bacillus.
5. A formulation according to any preceding claim, which comprises a fibre-digesting enzyme or a microorganism capable of producing a fibre-digesting enzyme.
6. A formulation according to any preceding claim, which additionally comprises lactoperoxidase.
7. A formulation according to any preceding claim, wherein each component thereof is resistant to the antibacterial products of the or each other component.
8. A formulation according to any preceding claim, wherein the or each component thereof is resistant to synthetic antibiotics used to combat pathogens of the gastrointestinal tract such as E. coli.
9. A formulation according to any preceding claim, characterised by the ability to reduce the growth rates of harmful enteric bacteria such as E. coli, Salmonella and Clostridia.
10. Use of the components defined in a formulation according to any preceding claim for the promotion of growth or weight gain in a farm animal.
11. A composition comprising the components of a formulation according to any preceding claim, for simultaneous, separate or sequential use in the treatment of an animal or human.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 93/00065

I. CLASSIFICATION F SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 A61K35/74; A23K1/16																							
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-bottom: 1px solid black; padding: 5px;">Classification System</td> <td style="border-bottom: 1px solid black; padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px;">Int.Cl. 5</td> <td style="padding: 5px;">A61K ; A23K</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched⁸</div>			Classification System	Classification Symbols	Int.Cl. 5	A61K ; A23K																	
Classification System	Classification Symbols																						
Int.Cl. 5	A61K ; A23K																						
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black; padding: 5px;">Category⁹</th> <th style="width: 70%; border-bottom: 1px solid black; padding: 5px;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 20%; border-bottom: 1px solid black; padding: 5px;">Relevant to Claim No.¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">EP,A,0 208 818 (SEIKENKAI FOUNDATIONAL JURIDICAL PERSON) 21 January 1987</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-5,7-11</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">see the whole document ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-11</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">US,A,4 808 417 (MASUDA) 28 February 1989 see the whole document ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-5,7-11</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">GB,A,1 040 278 (CENTRE EUROPEAN DE RECHERCHES MAUVERNAY) 24 August 1966 see the whole document ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-5,7-11</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">WO,A,8 911 858 (WHITECLIFFE LABORATORIES LIMITED) 14 December 1989 see page 2, paragraph 4 - page 4, paragraph 1 ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">5</td> </tr> <tr> <td colspan="2" style="text-align: center; padding: 5px;">---</td> <td style="text-align: center; padding: 5px;">-/--</td> </tr> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	EP,A,0 208 818 (SEIKENKAI FOUNDATIONAL JURIDICAL PERSON) 21 January 1987	1-5,7-11	Y	see the whole document ---	1-11	Y	US,A,4 808 417 (MASUDA) 28 February 1989 see the whole document ---	1-5,7-11	Y	GB,A,1 040 278 (CENTRE EUROPEAN DE RECHERCHES MAUVERNAY) 24 August 1966 see the whole document ---	1-5,7-11	Y	WO,A,8 911 858 (WHITECLIFFE LABORATORIES LIMITED) 14 December 1989 see page 2, paragraph 4 - page 4, paragraph 1 ---	5	---		-/--
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																					
X	EP,A,0 208 818 (SEIKENKAI FOUNDATIONAL JURIDICAL PERSON) 21 January 1987	1-5,7-11																					
Y	see the whole document ---	1-11																					
Y	US,A,4 808 417 (MASUDA) 28 February 1989 see the whole document ---	1-5,7-11																					
Y	GB,A,1 040 278 (CENTRE EUROPEAN DE RECHERCHES MAUVERNAY) 24 August 1966 see the whole document ---	1-5,7-11																					
Y	WO,A,8 911 858 (WHITECLIFFE LABORATORIES LIMITED) 14 December 1989 see page 2, paragraph 4 - page 4, paragraph 1 ---	5																					
---		-/--																					
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>																							
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center;">23 APRIL 1993</div> </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center;">17. 05. 93</div> </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;"> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="border-bottom: 1px solid black; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;">SITCH W.D.C.</div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center;">23 APRIL 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center;">17. 05. 93</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">SITCH W.D.C.</div>																	
Date of the Actual Completion of the International Search <div style="text-align: center;">23 APRIL 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center;">17. 05. 93</div>																						
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">SITCH W.D.C.</div>																						

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category ^o	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claims No.
Y	EP,A,0 397 227 (BIO SERAE LABORATOIRES SA) 14 November 1990 see claim 1 ---	6
Y	EP,A,0 290 410 (EWOS AKTIEBOLAG) 9 November 1988 see claims 1-5 -----	6

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9300065
SA 69251

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

23/04/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0208818	21-01-87	JP-B- 4029348	18-05-92
		JP-A- 60149527	07-08-85
		AU-A- 4503485	22-01-87
		US-A- 4871539	03-10-89

US-A-4808417	28-02-89	JP-A- 63164853	08-07-88
		JP-A- 63164854	08-07-88

GB-A-1040278		None	

WO-A-8911858	14-12-89	AU-A- 3836489	05-01-90

EP-A-0397227	14-11-90	FR-A- 2646777	16-11-90
		CA-A- 2014847	12-11-90
		JP-A- 3193708	23-08-91

EP-A-0290410	09-11-88	JP-A- 1132340	24-05-89
		SE-A- 8701839	06-11-88
		US-A- 4929466	29-05-90